Simply Speaking NASH
hosted byPractice Point Communications (PPC)
Simply Speaking NASH is organized by Practice Point Communications (PPC).
Accreditation:
Physicians:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Practice Point Communications.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses/Nurse Practitioners:
The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is provided for 1.0 contact hours under ANCC criteria. Provider approved by the California Board of Registered Nursing, Provider #13699 for 1.2 contact hours.
Note: The ANCC accreditation criteria compute 1 contact hour for each 60 minutes of learning activity. California requirements compute 1 contact hour for every 50 minutes of learning activity. Nurses should only claim credit consistent with the actual time they spent attending the learning activity.
Pharmacists (PharmDs/RPhs):
This knowledge-based activity is accredited for 1 hour of continuing pharmacy education (CPE) credit. Duquesne University School of Pharmacy will report all credit to CPE Monitor within 60 working days after receiving evidence of successful completion of the course. Successful completion means that you must attend the entire program and complete an evaluation form.
Overview:
Thank you for your interest in the CME lecture series titled Simply Speaking NASH. This series is available free of charge to a variety of institutions (clinics, hospitals, specialty organizations) wanting to improve healthcare provider education in the area of NASH. Simply Speaking NASH is certified for continuing medical education credit by the University of Nebraska Medical Center, Center for Continuing Education for endocrinologist, hepatologist and gastroenterologist physicians.
What is Simply Speaking NASH?
• An educational series accredited by University of Nebraska Medical Center (UNMC), Department of Continuing Medical Education
• Live, accredited CME and CE activities compliant with evolving ACCME Guidelines
• Regional educational opportunities for MD, DO, PA, NP, RN and PharmD healthcare professional
• A continuous, annually funded initiative with a dedicated Therapeutic Advisor and UNMC CME/CE Planning Committee that meets quarterly to discuss process, logistics and content enhancements and ongoing ACCME compliance
• A proven process of identifying, certifying and evaluating national and regional healthcare experts
Why participate in Simply Speaking NASH?
• Content development and training provided by well-known and credible educators participating within Simply Speaking®
• This series is available free of charge to a variety of institutions (clinics, hospitals, specialty organizations) wanting to improve health care provider education
Topics:
Advances in NASH: Disease Burden and Management Considerations:
Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the United States, where they are a growing cause of cirrhosis and hepatocellular carcinoma. Despite the alarming numbers of patients impacted, real therapeutic options are still limited because of its complexity and the high individual variability. This activity will discuss the NASH disease burden, diagnostic options and challenges to identifying those at risk for NASH, and current management approaches.
Clinical Trials in NASH: Lessons Learned and Clinical Implications:
Nonalcoholic steatohepatitis (NASH) is a multifactorial disease, and as such, unlikely that only one drug will be sufficient to treat most patients. Currently, there are no FDA-approved drugs for the treatment of NASH. However, several promising drug therapies for NASH targeting a broad array of targets are in clinical trials and are anticipated to pave the way for new and more effective treatment options. This activity will discuss the potential drug targets under clinical investigation, the latest clinical data, and clinical implications for future management approaches for NASH.
Noninvasive Measures of Disease Stage in NASH:
Liver biopsy is the gold standard to diagnose/monitor liver disease progression. However, it is a suboptimal method to perform in every patient with suspected nonalcoholic steatohepatitis (NASH). Developing accurate, safe and easily accessible non-invasive modalities to accurately diagnose, predict, and monitor NASH and associated fibrosis is of utmost importance in clinical practice and clinical research. This activity will discuss the advantage and limitations of current biomarkers and noninvasive imaging modalities in the diagnosis, staging, and management of NASH.